Ran Xie
About
Ran Xie is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Ran Xie has authored 32 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ran Xie's work include Thyroid Cancer Diagnosis and Treatment (9 papers), Radiomics and Machine Learning in Medical Imaging (5 papers) and Renal cell carcinoma treatment (4 papers). Ran Xie is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (9 papers), Radiomics and Machine Learning in Medical Imaging (5 papers) and Renal cell carcinoma treatment (4 papers). Ran Xie collaborates with scholars based in United States, China and Australia. Ran Xie's co-authors include Stephen M. Hewitt, Joon‐Yong Chung, Kris Ylaya, Nathan Nakatsuka, Natalie Guerrero, Reginald L. Williams, Marcia S. Brose, Christelle de la Fouchardière, Hanbyoul Cho and Su-Su Xie and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Ran Xie
27 papers receiving 667 citations
Peers
Ran Xie
Laurie L. Carr United States
Sharon B. Sams United States
Stephen Raskin Israel
Todd Riehl United States
Marko Buta Serbia
Matti L. Gild Australia
R. Molife United Kingdom
Prateek Mendiratta United States
Sang Soo Kim South Korea
Melissa M. Johnson United States
Citations per year, relative to Ran Xie Ran Xie (= 1×)
peers
Laurie L. Carr
Countries citing papers authored by Ran Xie
Since
Specialization
Citations
This map shows the geographic impact of Ran Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ran Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ran Xie more than expected).
Fields of papers citing papers by Ran Xie
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ran Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ran Xie. The network helps show where Ran Xie may publish in the future.
Co-authorship network of co-authors of Ran Xie
This figure shows the co-authorship network connecting the top 25 collaborators of Ran Xie. A scholar is included among the top collaborators of Ran Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ran Xie. Ran Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fu, Lixia, Songtao Dong, Ran Xie, et al.. (2025). A multi-dimensional comparative study of 505(b)(2) NDAs approved by FDA and Class 2 NDAs approved by NMPA from 2017 to 2023: Uncovering trends, characteristics, and regulation of modified new drugs. Regulatory Toxicology and Pharmacology. 162. 105864–105864.
2.
Zhu, Caiyun, et al.. (2024). Comparison of the recovery quality between remimazolam and propofol after general anesthesia: systematic review and a meta-analysis of randomized controlled trials. PeerJ. 12. e17930–e17930.
3.
Motzer, Robert J., Saby George, Jaime R. Merchan, et al.. (2023). Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. The Oncologist. 28(6). 501–509.
4.
Gao, Hongqiang, Ran Xie, Rong Huang, et al.. (2022). CIRBP Regulates Pancreatic Cancer Cell Ferroptosis and Growth by Directly Binding to p53. Journal of Immunology Research. 2022. 1–12.
5.
Guo, Chengxian, Qi Pei, Chan Zou, et al.. (2022). Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers. Frontiers in Pharmacology. 12. 797278–797278.
6.
Xie, Ran, Nan Zhao, Bo Jia, et al.. (2022). Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 48(1). 35–40.
7.
Wirth, Lori J., Marcia S. Brose, Eric J. Sherman, et al.. (2021). Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. Journal of Clinical Oncology. 39(21). 2359–2366.
8.
Taylor, Matthew H., Shunji Takahashi, Jaume Capdevila, et al.. (2021). Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 31(8). 1226–1234.
9.
Hutson, Thomas E., M. Dror Michaelson, Timothy M. Kuzel, et al.. (2021). A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. European Urology. 80(2). 162–170.
10.
Wang, Chun, Sheng Zhao, Ran Xie, et al.. (2021). The clinical application of 18F-FDG PET/CT in pancreatic cancer: a narrative review. Translational Cancer Research. 10(7). 3560–3575.
11.
Lee, Chung‐Han, Yin Wan, Alan D. Smith, Ran Xie, & Robert J. Motzer. (2021). Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. European Urology Open Science. 31. 1–9.
12.
O’Shaughnessy, Joyce, Javier Cortés, Chris Twelves, et al.. (2020). Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Scientific Reports. 10(1). 11203–11203.
13.
Xie, Ran, Suwei Dong, Jie Jiang, et al.. (2020). <p>Development and Validation of an Immune-Related Gene Pair Signature in Skin Cutaneous Melanoma</p>. Clinical Cosmetic and Investigational Dermatology. Volume 13. 973–986.
14.
Brose, Marcia S., Bhavana Konda, Christelle de la Fouchardière, et al.. (2020). 426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg. Annals of Oncology. 31. S1409–S1409.
15.
Smith, John W., Karen L. Tedesco, Soamnauth Misir, et al.. (2019). Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer. Clinical Breast Cancer. 20(2). 160–167.
16.
Zhao, Nan, Ran Xie, Hong Zhao, et al.. (2019). Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers. Clinical Drug Investigation. 39(7). 671–681.
17.
Braunschweig, Till, Joon‐Yong Chung, Chel Hun Choi, et al.. (2015). Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array. Diagnostic Pathology. 10(1). 53–53.
18.
Chung, Joon‐Yong, Joo Mi Yi, Ran Xie, et al.. (2012). A pressure cooking-based DNA extraction from archival formalin-fixed, paraffin-embedded tissue. Analytical Biochemistry. 425(2). 128–134.
19.
Xie, Ran, Joon‐Yong Chung, Kris Ylaya, et al.. (2011). Factors Influencing the Degradation of Archival Formalin-Fixed Paraffin-Embedded Tissue Sections. Journal of Histochemistry & Cytochemistry. 59(4). 356–365.
20.
Xie, Ran, Matthew Schlumbrecht, Gregory L. Shipley, et al.. (2009). S100A4 mediates endometrial cancer invasion and is a target of TGF-β1 signaling. Laboratory Investigation. 89(8). 937–947.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Laurie L. Carr Breakdown of academic impact, for papers by Sharon B. Sams Breakdown of academic impact, for papers by Stephen Raskin Breakdown of academic impact, for papers by Todd Riehl Breakdown of academic impact, for papers by Marko Buta Breakdown of academic impact, for papers by Matti L. Gild Breakdown of academic impact, for papers by R. Molife Breakdown of academic impact, for papers by Prateek Mendiratta Breakdown of academic impact, for papers by Sang Soo Kim Breakdown of academic impact, for papers by Melissa M. Johnson